Movano Health Granted Listing Extension by Nasdaq
Movano Health (Nasdaq: MOVE) has received a listing extension from the Nasdaq Hearings Panel to maintain its listing status. The company must meet two key conditions: file its Q1 and Q2 2025 quarterly reports by September 30, 2025, and demonstrate compliance with the $1.00 minimum bid price requirement by October 30, 2025.
To address the bid price requirement, Movano has scheduled a shareholder meeting for September 26, 2025, where stockholders will vote on a proposed reverse stock split. The company is actively working with its new auditor to complete and file the delayed quarterly reports within the extension period.
Movano Health (Nasdaq: MOVE) ha ottenuto un'estensione dalla Nasdaq Hearings Panel per mantenere la propria quotazione. La società deve rispettare due condizioni principali: depositare i rapporti trimestrali Q1 e Q2 2025 entro il 30 settembre 2025 e dimostrare la conformità al requisito del prezzo minimo di 1,00 USD per azione entro il 30 ottobre 2025.
Per soddisfare il requisito sul prezzo delle azioni, Movano ha convocato un'assemblea degli azionisti per il 26 settembre 2025, durante la quale gli azionisti voteranno una proposta di raggruppamento azionario inverso. La società sta collaborando con il nuovo revisore per completare e depositare i rapporti trimestrali ritardati entro il periodo di estensione.
Movano Health (Nasdaq: MOVE) ha recibido una prórroga del Nasdaq Hearings Panel para mantener su cotización. La compañía debe cumplir dos condiciones clave: presentar sus informes trimestrales Q1 y Q2 de 2025 antes del 30 de septiembre de 2025 y demostrar cumplimiento con el requisito de precio mínimo de 1,00 USD por acción antes del 30 de octubre de 2025.
Para abordar el requisito del precio de la acción, Movano ha programado una junta de accionistas para el 26 de septiembre de 2025, en la que los accionistas votarán una propuesta de reverse split. La compañía está trabajando con su nuevo auditor para completar y presentar los informes trimestrales atrasados dentro del periodo de prórroga.
Movano Health (Nasdaq: MOVE)� 상장 유지 조치� 위해 나스� 청문위원�(Nasdaq Hearings Panel)로부� 상장 연장 기간� 받았습니�. 회사� � 가지 주요 조건� 충족해야 합니�: 2025� 9� 30�까지 2025� 1분기 � 2분기 분기보고서를 제출하고, 2025� 10� 30�까지 주당 최소 호가 1.00달러 요건� 충족함을 입증해야 합니�.
호가 요건� 해결하기 위해 Movano� 2025� 9� 26� 주주총회� 소집� 주주들이 역병�(reverse stock split) 안건� 대� 표결하도� � 예정입니�. 회사� 연장 기간 내에 지연된 분기보고서를 완료하고 제출하기 위해 신규 감사인과 협력하고 있습니다.
Movano Health (Nasdaq: MOVE) a obtenu une prolongation du Nasdaq Hearings Panel pour conserver sa cotation. La société doit satisfaire deux conditions principales : déposer ses rapports trimestriels T1 et T2 2025 avant le 30 septembre 2025 et démontrer le respect de l'exigence de prix minimum de 1,00 USD par action avant le 30 octobre 2025.
Pour répondre à l'exigence de prix, Movano a convoqué une assemblée d'actionnaires le 26 septembre 2025, au cours de laquelle les actionnaires voteront une proposition de regroupement inverse d'actions. La société travaille activement avec son nouvel auditeur pour finaliser et déposer les rapports trimestriels retardés pendant la période de prolongation.
Movano Health (Nasdaq: MOVE) hat von dem Nasdaq Hearings Panel eine Fristverlängerung erhalten, um die Notierung aufrechtzuerhalten. Das Unternehmen muss zwei zentrale Bedingungen erfüllen: die Einreichung der Quartalsberichte Q1 und Q2 2025 bis zum 30. September 2025 und den Nachweis der Einhaltung der Mindestgebotspreis-Anforderung von 1,00 USD bis zum 30. Oktober 2025.
Um die Anforderung zum Aktienkurs zu erfüllen, hat Movano eine Hauptversammlung für den 26. September 2025 angesetzt, bei der die Aktionäre über einen vorgeschlagenen Reverse Stock Split abstimmen werden. Das Unternehmen arbeitet aktiv mit seinem neuen Abschlussprüfer zusammen, um die verspäteten Quartalsberichte innerhalb der Verlängerungsfrist fertigzustellen und einzureichen.
- Nasdaq granted extension for continued listing
- Company has clear path to maintain Nasdaq listing through compliance plan
- Active steps being taken with new auditor to file delayed reports
- Company is delinquent in filing Q1 and Q2 2025 quarterly reports
- Stock trading below $1.00 minimum bid price requirement
- Potential reverse stock split may be necessary to maintain listing
The Panel's determination follows a hearing on August 19, 2025, at which the Panel considered the Company's plan to regain compliance with the Periodic Filing Rule and the Bid Price Rule. The Company has and continues to work diligently with its new auditor to complete and file with the Securities and Exchange Commission ("SEC") its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, and June 30, 2025, and expects to do so within the extension period granted by the Panel. Additionally, on August 19, 2025, the Company filed a Preliminary Proxy Statement for its Annual Shareholders Meeting to be held on September 26, 2025, at which the Company's shareholders will have the opportunity to approve a reverse stock split proposal, the effect of which will allow the Company to demonstrate compliance with the Bid Price rule within the extension period granted by the Panel.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health, maker of the Evie Ring (), is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.
Movano Health's proprietary technologies and wearable medical device solutions will soon enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit .
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements relating to the Company's plan to regain compliance with Nasdaq's rules and the timing thereof. Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including but not limited to the potential inability to meet Nasdaq's requirements within the extension period granted by the Nasdaq Panel; uncertainties associated with the Company's preparation of the delinquent filings; uncertainties associated with achieving the required shareholder vote necessary to approve a reverse stock split proposal and the possibility of additional delays in the filing of the delinquent filings and the Company's other SEC filings. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View original content to download multimedia:
SOURCE Movano